Cardiovascular Implications of Proteinuria

Similar documents
1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria

Management of New-Onset Proteinuria in the Ambulatory Care Setting. Akinlolu Ojo, MD, PhD, MBA

REVIEW ARTICLE NEWER BIOMARKERS IN EARLY DIABETIC NEPHROPATHY

Kidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)

Managing Chronic Kidney Disease: Reducing Risk for CKD Progression

Morbidity & Mortality from Chronic Kidney Disease

CARDIO-RENAL SYNDROME

ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour

E.Ritz Heidelberg (Germany)

AGING KIDNEY IN HIV DISEASE

6/10/2014. Chronic Kidney Disease - General management and standard of care. Management of CKD according to stage (KDOQI 2002)

Predicting and changing the future for people with CKD

Diabetic Nephropathy

Ο ρόλος των τριγλυκεριδίων στην παθογένεια των μικροαγγειοπαθητικών επιπλοκών του σακχαρώδη διαβήτη

Cardiovascular Protection and the RAS

Diabetes and kidney disease.

Evaluation of Chronic Kidney Disease KDIGO. Paul E de Jong University Medical Center Groningen The Netherlands

Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015

Diabetic Nephropathy. Objectives:

A New Approach for Evaluating Renal Function and Predicting Risk. William McClellan, MD, MPH Emory University Atlanta

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality

Objectives. Kidney Complications With Diabetes. Case 10/21/2015

SLOWING PROGRESSION OF KIDNEY DISEASE. Mark Rosenberg MD University of Minnesota

Focal Segmental Glomerulosclerosis and the Nephro6c Syndrome Dr. A. Gangji Dr. P. Marge>s

1.6 > < ESRD. < >2.0 ESRD Serum creatinine mg/dl

renoprotection therapy goals 208, 209

TREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009

23-Jun-15. Albuminuria Renal and Cardiovascular Consequences A history of progress since ,490,000. Kidney Center, UMC Groningen

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

Diabetes and Hypertension

Chapter 1: CKD in the General Population

Renal Physiology - Lectures

Dr P Sigwadi Paediatric Nephrology

The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009

Managing patients with renal disease

Uric acid and CKD. Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George

RENAL PHYSIOLOGY WESTMEAD PRIMARY EXAM

ROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret

Diabetic Nephropathy

JOSHUA K. KAYIMA INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY

Cardiovascular Complications Of Chronic Kidney Disease. Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen

Cardiovascular disease and diabetes Vascular harmony

Outline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?

Stages of Chronic Kidney Disease (CKD)

Guest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2

Addressing Chronic Kidney Disease in People with Multiple Chronic Conditions

CVD risk assessment using risk scores in primary and secondary prevention

SPRINT: Consequences for CKD patients

Fasting or non fasting?

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?

Blood Pressure Monitoring in Chronic Kidney Disease

Metabolic Syndrome and Chronic Kidney Disease

Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine

Disclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW

Cardiovascular Mortality: General Population vs ESRD Dialysis Patients

The Diabetes Link to Heart Disease

Disclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW

For more information about how to cite these materials visit

10/17/16. Assessing cardiovascular risk through use of inflammation testing

Microalbuminuria As Predictor Of Severity Of Coronary Artery Disease In Non-Diabetic Patients:

American Academy of Insurance Medicine

Diabetic Nephropathy

Diabetes and Kidney Disease. Kris Bentley Renal Nurse practitioner 2018

Vascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital

CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW

T. Suithichaiyakul Cardiomed Chula

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Case Studies: Renal and Urologic Impairments Workshop

The Role of Vitamin D in Heart Disease. Janet Long, MSN, ACNP, CLS, FAHA, FNLA Cardiovascular Institute Rhode Island Hospital and The Miriam Hospital

Dr. Mehmet Kanbay Department of Medicine Division of Nephrology Istanbul Medeniyet University School of Medicine Istanbul, Turkey.

Outline. Outline. Introduction CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/11/2011

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

Interventions to reduce progression of CKD what is the evidence? John Feehally

Reframe the Paradigm of Hypertension treatment Focus on Diabetes

SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection

Podocyte Biology and clinical applications Dr. F. Ahmadi Professor Of Nephrology TUMS

Diabetes Mellitus: A Cardiovascular Disease

RENAL HISTOPATHOLOGY

CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH

ADVANCE post trial ObservatioNal Study

Diabetic Kidney Disease in the Primary Care Clinic

Copyright 2009 Pearson Education, Inc. Copyright 2009 Pearson Education, Inc. Figure 19-1c. Efferent arteriole. Juxtaglomerular apparatus

Kidney Disease, Hypertension and Cardiovascular Risk

Correlation of novel cardiac marker

Hypertension Management in Diabetic Patients

Urinary Physiology. Chapter 17 Outline. Kidney Function. Chapter 17

Prof. Andrzej Wiecek Department of Nephrology, Endocrinology and Metabolic Diseases Medical University of Silesia Katowice, Poland.

The hypertensive kidney and its Management

How to Reduce CVD Complications in Diabetes?

The Link Between Acute and Chronic Kidney Disease. John Arthur, MD, PhD

Cardiovascular Diseases in CKD

Summary of Recommendation Statements Kidney International Supplements (2013) 3, 5 14; doi: /kisup

Year 2004 Paper one: Questions supplied by Megan

Primary Care Approach to Management of CKD

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

Running head: NEPHRON 1. The nephron the functional unit of the kidney. [Student Name] [Name of Institute] Author Note

2/9/2017. Financial Disclosures/Unapproved Use. Achieving Harmony in Blood Pressure Guidelines Around the Globe. Roger S. Blumenthal, MD.

Pattern of urinary albumin excretion in non-diabetic first-degree relatives of type 2 diabetes mellitus patients

Transcription:

Cardiovascular Implications of Proteinuria B. S. Kasinath, MD University of Texas Health Science Center South Texas Veterans Health Care System San Antonio Objectives Mechanisms of albumin handling by the kidney Discuss the CV implications of proteinuria in non Chronic Kidney Disease patients and possible interventions No disclosures

Glomerular ultrafiltration Glomerulus Unique capillary interposed between 2 arterioles Podocytes Glom Basement Membrane Endothelial cells Mesangial cells Haraldsson B, Physiol Rev 88: 451, 2008 Role of resistance vessels Proteinuria mechanisms Role of podocyte Slit diaphragm Diabetic nephropathy, Gene mutations, e.g., NPHS1 (nephrin), NPHS2 (podocin) Role of glomerular endothelial cells Anionic glycocalyx: charge barrier Loss of fenestrae, impaired glycocalyx Diabetic nephropathy, Pre eclampsia, TTP, HUS Alb Size and Charge Barrier Podocyte: slit diaphragm Human glomerular proteome contains 144 matrix proteins: contribution to proteinuria? Salmon AHJ, Satchell SC, J Pathol 226: 562, 2012 Glomerulus: a size and charge selective barrier Glycocalyx: Glom. endoth cells, podocyte Pollak MR, Clin J Am Soc Nephrol 9: 1461, 2013, Lennon R. J Am Soc Nephrol 25: 953. 2014

Cubilin Proteinuria mechanisms Proximal Tubule Reabsorbs Filtered Albumin Megalin, Cubilin system brush border Endocytosis and delivery of cargo to lysosomes for degradation Recycling of Megalin and Cubilin Reabsorbed Proteins: Albumin, Carrier proteins and others Estimate in humans: ~0.5 1 g albumin filtered & absorbed PT specific Meg or Cub KO: albuminuria, low mol. wt. proteins Other albumin transporters: Neonatal Fc receptor Ab Toxic effects of proteinuria on Proximal Tubular Cells Complement activation, Inflammation, TGFβ Activation of RAAS, fibroblast stimulation Renal interstitial fibrosis: CKD progression Nielsen R, Kidney Int 89: 58, 2016, Zoja C, Nephrol Dial Transplant 30: 706, 2015 Proteinuria Urinary proteins: Albumin, Uromodulin (T H protein), traces of other proteins Pathologic proteinuria: albumin, Igs, myoglobin, light chains Dipstick + protein: loss of renal function >5%/ year from baseline (Clark) Albuminuria: Urinary Albumin Creatinine Ratio (ACR) ACR in CKD: >30 mg/g Staging of CKD now coupled to ACR (A1 0 30, A2 30 300, A3 >300 mg/g) Focus: Albuminuria in Cardiovascular Disease (CVD) Clark WF, J Am Soc Nephrol 22: 1729, 2011, Megalin

Albuminuria Implications for CVD What is the rationale for looking at albuminuria in CVD? 1. Accurate risk assessment of CVD in general population is critical for optimal preventive and therapeutic strategies 2. Even after identifying and treating traditional risk factors there is significant residual morbidity and mortality due to CVD 3. This suggests there must non traditional risk factors. 4. We need for new biomarkers: fit for large scale screening accessible 5. ACR measurement is widely available and a good candidate for examination Albuminuria Urinary albumin excretion in the General Population 7265 subjects from Japan 11,392 subjects, ARIC study from US Urinary ACR mg/g Percent Urinary ACR mg/g Percent <5 53.2% <10 79.9% 5 10 21.8% 10 29 12% 11 20 8.7% 30 299 6.5% >300 1.6% CKD 21 30 2.6% 30 300 4.6% >300 0.5% Undetectable urinary albumin in 8.8% 80% of population: ACR is <10 mg/g CKD range ACR in 5.1% CKD 80% of population: ACR is <10 mg/g CKD range ACR in 8.1% Tanaka S, BMC Res Notes 6: 256, 2013, Matsushita K, Am J Kidney Dis 55: 648, 2010 (Atherosclerosis Risk in Communities)

Albuminuria and CVD Studies in General Population ACR >30 mg/g: independent risk factor for CVA, MI, death and predicts future CHF Is non CKD level of ACR associated with diseases? HOPE study: 3498 diabetic and 5545 non diabetic, Follow up 4.5 years, Microalbuminuria (ACR >18mg/g): 30% diabetics, 15% non diabetics Analysis of ACR in deciles: An Independent Continuous Risk Factor (well below CKD definition) for CVD, All Cause Mortality and CHF admission after adjusting for other risk factors?confirmation by other studies normal range Gerstein HC, JAMA 286: 421, 2001 Albuminuria and Mortality Studies in General Population Meta analysis of 21 large studies (international) 1.2 million subjects, F/U 8 years, age 61 years Baseline ACR Or dipstick for protein vs. All Cause or CV mortality (hazard ratio, HR) Baseline egfr vs. All Cause or CV Mortality 68% of subjects had ACR <10 mg/g normal range After adjusting for age, sex, ethnicity, h/o CVD, BP, diabetes, smoking, total cholesterol CV and AC mortality progressively rose beyond ACR of 5 mg/g Note increased death WITHIN normal range of ACR (5 vs. 10 vs. 30) Matsushita K, Lancet 375: 2073, 2010

Albuminuria and Mortality Studies in General Population Adjusted for age, sex, ethnicity, h/o CVD, BP, diabetes, smoking, total cholesterol Greater ACR is associated with greater mortality at each egfr range including in the 90 120 range Dipstick + Proteinuria Even trace proteinuria increases HR for All Cause and CV mortality across egfr categories Matsushita K, Lancet 375: 2073, 2010 Albuminuria and Mortality Conclusions of Matsushita study 1. 2. 3. ACR /dipstick + proteinuria are independent risk factors for All Cause & Cardiovascular mortality egfr is also an independent risk factor Is ACR of 5 mg/g the threshold for predicting Cardiovascular and All Cause mortality? Issues: No uniform measurement of albumin, creatinine and protein among studies employed in meta analysis Reliance on dipstick?evidence from a study that did not have these issues? Matsushita K, Lancet 2010; 375: 2073, 2010

Albuminuria and CVD in General Population Studies in General Population (South Korea) Single Center study 37091 people, 53% men, mean age 46, F/u 5 yrs, All had ACR below 30 mg/g Analysis done after adjusting for smoking, obesity, education, egfr Albuminuria in the normal range (<30 mg/g) divided into quartiles Note: 75% of people had ACR less than 7.4 mg/ g creatinine BMI and higher BP associated with higher quartiles within this normal range of ACR Sung K C, J Am Heart Assoc 5: e003245, 2016 Albuminuria and CVD in General Population Albuminuria in normal range and mortality Adjusted for age, sex, smoking, obesity, education, alcohol, exercise, BMI, HT, DM, history of CVD, HDL/ LDL cholesterol, egfr Highest quartile (ACR >7 mg/g): 3.4 fold higher risk for CV mortality CVD mortality: Note rising risk from Q1 through Q4 even in this normal range?a dose effect No threshold : continuous risk factor No such risk for All Cause mortality Sung K C, J Am Heart Assoc 5: e003245, 2016

Albuminuria and CVD in General Population Risk for Hypertension (9102 subjects followed for 3 years) Adjusted for age, sex, smoking, obesity, education, alcohol, exercise, BMI, HT, HDL/ LDL chol, egfr Highest quartile (ACR 7 ug/g): 1.97 fold higher risk for HT Note rising risk across the quartiles suggests a dose effect No Risk for Diabetes (10930 subjects followed for 3 years Sung K C, J Am Heart Assoc 5: e003245, 2016 Albuminuria, CVD in General Population Problems with general population studies Urinary ACR commonly measured once not confirmed on repeat test Does not account for diurnal variation, factors such as exercise, fever Variability of albuminuria is high; false + 30 50% However, large numbers of subjects mitigate variability BP data based on one time measurement egfr estimates are not reliable in the range seen Is ACR is risk factor for CVD and mortality? Still open NephSAP 2016

Albumin does it cause microvascular injury? Why is albuminuria associated with CVD? Possible scenarios?just a marker for associated CVD risk factors HT, diabetes, CKD, dyslipidemia Steno hypothesis: Albuminuria associates with global dysfunction of endothelium Albumin is directly injurious to blood vessels Potential causative role of Albumin Normally, Albumin scavenges ROS Oxidation of albumin occurs on Cys 34 Circulating plasma oxidized albumin correlates with CVD (Kaneda, Lim) Atheroma proteomics: albumin is abundant in the plaque (Lepedda 2009) Oxidative environment in Atheroma: Plaque albumin: Cys 34 oxidation 3 fold higher vs. plasma albumin These data show: Albumin enters into the atherosclerotic plaque and it is highly oxidized Lepedda AJ, Atherosclerosis 203: 112, 2009; Lepedda AJ, Oxid Med Cell Longevity 2014; 69053, Kaneda H, Atherosclerosis 162: 221, 2002; Lim P S, PLOS ONE 8: e70822, 2013 Albuminuria does it cause microvascular injury? Toxic effects of albumin Endothelial cells exposed to Oxidized Alb Increased VCAM 1, ICAM 1 expression Entry of monocytes into vessel wall Increased ROS generation; apoptosis Oxidative stress in endothelial cells Prox Tub Epithelial cells albumin overload mtorc1 activn, NFkB, infl. chemokines Albuminuria may be associated with albumin entry into the vessel wall Circulating oxidized albumin may injure endothelial cells & promote monocyte entry Oxidized Albumin in the vessel wall may contribute to atherosclerosis Luna C, Clin Interven Aging 11: 225, 2016, Moore KJ, Nat Rev Immunol 13: 709, 2013; Peruchetti DB, J Biol Chem 289: 16790, 2014

Conclusion 1 Albuminuria could be a continuous independent risk factor for cardiovascular disease and mortality Classifying albuminuria as normal under 30 mg/g may be debatable with regards to Cardiovascular Disease Methodological issues should be settled before future studies are done, e.g., assay procedure, collection time, repeat test for confirmation timing of repeat ACR Conclusion 2 Should we measure albuminuria as risk factor for CVD? Need prospective studies to show improved risk stratification for CVD Management: Need data from prospective trials that show improved CVD outcomes when albuminuria is treated (ACE inhibitors, ARBs) Otherwise, large segments of population with low albuminuria will be exposed to the risks of toxicity and costs The value of albuminuria in CVD risk prediction and management needs further examination

Thank You Albuminuria and CVD Albuminuria and Cardiovascular Disease in Hispanic Americans Echo Sol Study 1815 subjects, 4 sites Normal (42%), High normal (<17mg/g) (43%), microalbuminuria (13%), macroalbuminuria (>250 mg/g) (2%) Micro and macro albuminuria associated with LVH on echo High normal and above: diastolic dysfunction Hanna DB, Am J Cardiol, March 2017, http://dx.doi.org/10.1016/j.amjcard.2017.03.039

Mechanisms of Endothelial Injury in Diabetes ACR and CVD Since ACR is a continuous risk factor, it will not discriminate between people at risk for CVD vs. those who do not. Not so; the HR increases as ACR increases. Thus, one can identify those above the reference range (e.g., <3 mg/g) and test for CVD association >3 mg/g range will cover millions of people Proof needed to show reducing albuminuria ameliorates injury in non renal blood vessels that develop atherosclerosis Mechanisms of Endothelial Injury in Diabetes Loss of fenestrae and glycocalyx Macrophage secretion of cathepsin S, activation of protease activated receptor 2, results in albuminuria VEGF: variable role in early vs. late stages NO deficiency: High glucose scavenges NO leading to inflammation, platelet aggregation, reduced angiogenesis, TGFb activation, coagulation Uncoupling of enos: formation of peroxinitrite AGE induced senescence, rescued by SIRT 1 Goligorsky, M, Am J Physiol Renal Physiol 312: F266,2017

Unused slides